Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prestige Consumer Healthcare (PBH) Capital Expenditures: 2010-2025

Historic Capital Expenditures for Prestige Consumer Healthcare (PBH) over the last 16 years, with Sep 2025 value amounting to $2.1 million.

  • Prestige Consumer Healthcare's Capital Expenditures rose 3.70% to $2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.0 million, marking a year-over-year decrease of 4.00%. This contributed to the annual value of $8.2 million for FY2025, which is 13.88% down from last year.
  • Per Prestige Consumer Healthcare's latest filing, its Capital Expenditures stood at $2.1 million for Q3 2025, which was up 150.84% from $838,000 recorded in Q2 2025.
  • In the past 5 years, Prestige Consumer Healthcare's Capital Expenditures registered a high of $4.9 million during Q1 2021, and its lowest value of $838,000 during Q2 2025.
  • Moreover, its 3-year median value for Capital Expenditures was $2.0 million (2024), whereas its average is $2.1 million.
  • As far as peak fluctuations go, Prestige Consumer Healthcare's Capital Expenditures tumbled by 69.64% in 2021, and later surged by 41.07% in 2023.
  • Over the past 5 years, Prestige Consumer Healthcare's Capital Expenditures (Quarterly) stood at $2.2 million in 2021, then decreased by 19.11% to $1.8 million in 2022, then rose by 10.70% to $2.0 million in 2023, then decreased by 21.54% to $1.6 million in 2024, then rose by 3.70% to $2.1 million in 2025.
  • Its last three reported values are $2.1 million in Q3 2025, $838,000 for Q2 2025, and $3.5 million during Q1 2025.